ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

11,549Medicare Part D Prescriptions Filled, Including Refills

Rank: 38 out of 393

$511K Total Retail Price of All Prescriptions

Rank: 58 out of 393

748 Patients Receiving at Least One Drug in Part D
89%Patients 65 Years and Older
18% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Nevada
Lower avg

Schedule Two
Controlled Substances

4% of this provider’s 748 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

14% of this provider’s 748 patients filled at least one prescription for a schedule three drug, compared to an average of 14%.

Risky Drugs to Seniors

1% of this provider’s 10,426 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

13% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$44 was the average price of a prescription from this provider, compared to $54 among peers.

Prescriptions per Patient

15 is the average number of prescriptions (including refills) per patient, compared to an average of 15.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Nevada
LISINOPRIL 676 604 1 2
LOVASTATIN 615 560 2 14
SIMVASTATIN 518 497 3 1
LEVOTHYROXINE SODIUM 507 489 4 3
AMLODIPINE BESYLATE 501 484 5 4
LOSARTAN POTASSIUM 486 442 6 12
HYDROCODONE-ACETAMINOPHEN 456 390 S3 7 5
ATENOLOL 449 409 8 13
METFORMIN HCL 323 290 9 7
HYDROCHLOROTHIAZIDE 296 238 10 10
OMEPRAZOLE 293 266 11 6
GABAPENTIN 241 206 12 15
ZOLPIDEM TARTRATE 212 202 13 11
METOPROLOL TARTRATE 211 202 14 9
CITALOPRAM HBR 180 169 15 23
ALENDRONATE SODIUM 154 141 16 16
AZITHROMYCIN 146 132 17 35
MELOXICAM 138 129 18 58
FUROSEMIDE 133 117 19 8
GEMFIBROZIL 127 117 20 62
DONEPEZIL HCL 117 117 21 34
CIPROFLOXACIN HCL 111 102 22 57
WARFARIN SODIUM 99 90 23 17
GLIPIZIDE 96 80 24 32
PRAVASTATIN SODIUM 91 76 25 18
GLYBURIDE 90 80 R 26 46
TAMSULOSIN HCL 88 84 27 25
SERTRALINE HCL 86 79 28 28
LISINOPRIL-HYDROCHLOROTHIAZIDE 84 82 29 24
PROAIR HFA 82 70 30 68
VERAPAMIL ER 79 75 31 86
IBUPROFEN 75 53 32 55
NAMENDA 71 71 33 59
ALLOPURINOL 70 68 34 26
EVISTA 69 69 35 98
DIGOXIN 69 69 35 66
TRAMADOL HCL 68 60 37 30
TERAZOSIN HCL 67 67 38 38
LOSARTAN-HYDROCHLOROTHIAZIDE 66 66 39 31
CARVEDILOL 66 54 39 21
ATORVASTATIN CALCIUM 63 58 41 19
ADVAIR DISKUS 62 56 42 53
METOPROLOL SUCCINATE 61 58 43 22
AMOXICILLIN 58 49 44 174
POTASSIUM CHLORIDE 55 52 45 20
CLOPIDOGREL 52 48 46 33
RANITIDINE HCL 52 36 46 29
OXYCODONE HCL-ACETAMINOPHEN 52 30 S2 46 54
OXYBUTYNIN CHLORIDE 52 52 46 90
FLUOXETINE HCL 51 33 50 37
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 19, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.